Home>>Peptides>>MART-1 (26-35) (human) TFA

MART-1 (26-35) (human) TFA

Catalog No.GC36544

MART-1 (26-35) (human) TFA is amino acid residue 26 to 35 of MART-1 protein.

Products are for research use only. Not for human use. We do not sell to patients.

MART-1 (26-35) (human) TFA Chemical Structure

Size Price Stock Qty
1mg
$83.00
In stock
5mg
$334.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MART-1 (26-35) (human) TFA is amino acid residue 26 to 35 of MART-1 protein.

MART-1 (Melan-A) gene is 18 kb long and comprises five exons. It is expressed in most melanoma tumor samples, and among normal cells, only in melanocytes [1] . In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. The epitopes spanning amino acid residues 26-35 and 27-35 from the MART-1/Melan-A protein, highly expressed in melanoma cells, provide a prime example of T cell recognition of multiple peptides and the use of peptide variants designed to elicit altered immunological responses [2] .

[1]. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994 Jul 1;180(1):35-42. [2]. Borbulevych OY, et al. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol. 2007 Oct 5;372(5):1123-36.

Reviews

Review for MART-1 (26-35) (human) TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MART-1 (26-35) (human) TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.